<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132830</url>
  </required_header>
  <id_info>
    <org_study_id>2019P000629</org_study_id>
    <nct_id>NCT04132830</nct_id>
  </id_info>
  <brief_title>HIV Exposure In Utero and Metabolic Disease Risk in HIV-Negative Young Adults</brief_title>
  <acronym>HIV HEREDITY</acronym>
  <official_title>HIV Exposure In Utero and Metabolic Disease Risk in HIV-Negative Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Globally, over 1 million babies are born to mothers with HIV each year. With the advent of
      prenatal antiretroviral therapy, up to 98% of these individuals may be HIV-exposed uninfected
      (HEU). A growing literature suggests that in utero HIV exposure - even in the absence of
      subsequent infection - may be associated with adverse health outcomes in infancy and
      childhood. However, there is little information about the long-term health implications of in
      utero HIV exposure later in life, such as into adulthood. In this study, for the first time,
      we seek to prospectively evaluate metabolic and immune indices among HEU young adults as
      compared to well-matched HIV-unexposed uninfected controls. This study serves as a necessary
      first step toward optimizing clinical care for this expanding and aging HEU population,
      including the implementation of novel screening and prevention strategies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index (BMI)</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Activated CD8+ T cells</measure>
    <time_frame>Baseline</time_frame>
    <description>Flow cytometry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abdominal fat mass</measure>
    <time_frame>Baseline</time_frame>
    <description>Dual-energy x-ray absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose tolerance</measure>
    <time_frame>Baseline</time_frame>
    <description>Oral glucose tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids</measure>
    <time_frame>Baseline</time_frame>
    <description>Standard lipid panel (including HDL, triglycerides)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline</time_frame>
    <description>Systolic and diastolic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic fat content</measure>
    <time_frame>Baseline</time_frame>
    <description>Transient elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic fibrosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Transient elastography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell subsets</measure>
    <time_frame>Baseline</time_frame>
    <description>Flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>Baseline</time_frame>
    <description>ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Asthma</measure>
    <time_frame>Baseline, Ever</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DNA methylation patterns</measure>
    <time_frame>Baseline</time_frame>
    <description>Epigenome-wide analysis</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>HIV-exposed Uninfected</condition>
  <arm_group>
    <arm_group_label>HIV-Exposed Uninfected Dyads</arm_group_label>
    <description>Mothers who had HIV during pregnancy and their HIV-negative young adult offspring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV-Unexposed Uninfected Dyads</arm_group_label>
    <description>Mothers and young adults without HIV</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        We are recruiting mothers who had HIV during pregnancy and their HIV-negative young adult
        offspring (18-30 years old). We are also recruiting mothers and their young adult offspring
        without HIV to serve as controls.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        HIV-Exposed Uninfected (HEU) Mother-Young Adult Dyads

          1. Male or female young adult, 18-30 years old

          2. Documentation of HIV infection in mother with date of diagnosis preceding young adult
             birth date

          3. Negative HIV test in young adult

        Control Mother-Young Adult Dyads

          1. Matching to HEU dyad

          2. Negative HIV test in mother and young adult

        EXCLUSION CRITERIA:

        All Young Adults

          1. History of being adopted

          2. Pregnancy within 6 months or active nursing

          3. Change in blood glucose or blood pressure medication within 3 months

          4. Change in estrogen or testosterone therapy within 3 months

          5. Glucocorticoids (except steroid inhalers or creams) within 3 months

          6. Antiretroviral therapy use within 6 months (i.e., prophylaxis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay T Fourman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsay T Fourman, MD</last_name>
    <phone>617-643-4590</phone>
    <email>LFourman@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Isabel Zheng</last_name>
    <phone>67-643-4420</phone>
    <email>IZheng@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay T Fourman, MD</last_name>
      <phone>617-643-4590</phone>
      <email>LFourman@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 7, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Lindsay Fourman, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV-exposed Uninfected</keyword>
  <keyword>In Utero Exposure</keyword>
  <keyword>Metabolic</keyword>
  <keyword>Immune</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

